In this episode, Richard Church, Andrew Ruskin, and Victoria Hamscho discuss recent developments in the 340B Drug Pricing Program, including recent actions by drug manufacturers to limit contract pharmacy access to 340B pricing and impose new reporting requirements on 340B covered entities, as well as a new legislative proposal that would temporarily waive 340B hospital eligibility requirements.

Presenters: Richard Church, Andrew Ruskin, Victoria Hamscho

Podden och tillhörande omslagsbild på den här sidan tillhör K&L Gates. Innehållet i podden är skapat av K&L Gates och inte av, eller tillsammans med, Poddtoppen.